



ORAL PRESENTATION

Open Access

Antibodies to the envelope protein protect macaques from SIV_{mac251} acquisition in an immunization regimen that mimics the RV-144 Thai trial

G Franchini^{1*}, P Pegu¹, S Gordon¹, B Keele², M Doster¹, Y Guan³, G Ferrari⁴, R Pal⁵, MG Ferrari⁶, S Whitney⁷, L Hudacik⁷, E Billings⁸, M Rao⁸, D Montefiori⁹, D Venzon¹, C Fenizia¹, J Lifson², D Stablein², J Tartaglia¹⁰, N Michael¹¹, J Kim¹²

From AIDS Vaccine 2012
Boston, MA, USA. 9-12 September 2012

Background

The canarypox vector ALVAC-HIV, together with the HIV gp120 envelope, has protected 31.2% of Thai heterosexual individuals from HIV acquisition in the RV144 HIV vaccine trial. This outcome was unexpected, given the limited ability of the ALVAC-HIV vaccine component to induce CD8+T-cell responses, and of the HIVgp120 envelope to elicit broad neutralizing antibodies.

Methods

We vaccinated macaques with an immunization regimen that mimics the RV144 trial and exposed them to a mucosal dose of SIV_{mac251} that transmits few virus variants, similar to HIV transmission to humans.

Results

Vaccination induced anti-envelope antibodies, modest CD4+ and CD8+ T-cell responses. One third of the vaccinated macaques were protected from SIV_{mac251} acquisition, whereas the remaining infected vaccinees progressed to disease. Vaccine induced SIV_{mac251} specific T- and B-cell responses were not different in protected or infected animals. The sera of the animals protected had higher avidity antibodies to the gp120 envelope protein, recognized the variable envelope region V2, and reduced SIV_{mac251} infectivity in cells that express high level of $\alpha 4\beta 7$, suggesting a functional role to antibodies to V2.

Conclusion

The SIV_{mac251} infection macaque faithfully reproduces results in humans, and is instrumental in the development of more efficacious vaccines for HIV.

Author details

¹NCI/NIH, Bethesda, MD, USA. ²NCI-Frederick, Frederick, MD, USA. ³Institute of Human Virology Maryland University School of Medicine, Baltimore, MD, USA. ⁴Duke University, Durham, NC, USA. ⁵Advanced Bioscience Laboratories, Rockville, MD, USA. ⁶ABL, Rockville, MD, USA. ⁷Advanced Biosciences Laboratories, Rockville, MD, USA. ⁸Army Institute of Research, Silver Spring, MD, USA. ⁹Duke University Medical Center, Durham, NC, USA. ¹⁰Sanofi Pasteur Inc, Swifiter, PA, USA. ¹¹Walter Reed Army Institute of Research, Silver Spring, MD, USA. ¹²Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-O2

Cite this article as: Franchini et al.: Antibodies to the envelope protein protect macaques from SIV_{mac251} acquisition in an immunization regimen that mimics the RV-144 Thai trial. *Retrovirology* 2012 **9**(Suppl 2):O2.

¹NCI/NIH, Bethesda, MD, USA

Full list of author information is available at the end of the article